Roche Group said on Monday that it plans to invest more than $700 million in a new drug manufacturing facility in North Carolina, the latest drugmaker to expand its presence in the United States amid President Donald Trump's tariff policies.

Genentech unit plans to invest more than $700M in a new drug manufacturing facility in Holly Springs, North Carolina. The announcements reflect a broader wave of major investments by pharmaceutical companies like Eli Lilly  (LLY),

The commitment is part of Roche’s recently announced $50 billion investment in the U.S., but a company spokesperson said that could change if certain yet-unspecified policies are implemented that could “harm our industry’s ability to operate and innovate in America.